Epidemiology of first- and second-generation antipsychotic agents in Lombardy, Italy

Pharmacopsychiatry

Volumn 38, Issue 3, 2005, Pages 128-131

  Percudani, Mauro ^a,c   Barbui, C ^b   Fortino, I ^a   Petrovich, L ^a  

^a Health Care Directorate   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c Regione Lombardia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BROMPERIDOL; CHLORPROMAZINE; CLOTIAPINE; CLOZAPINE; DIXYRAZINE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PROMAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TIAPRIDE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DRUG COST; DRUG USE; FEMALE; HEALTH CARE COST; HUMAN; INFANT; ITALY; MAJOR CLINICAL STUDY; MALE; POPULATION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEX RATIO;

ADOLESCENT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNITY MENTAL HEALTH SERVICES; CONFIDENCE INTERVALS; DATABASES; DRUG UTILIZATION; FEMALE; HUMANS; INFANT; ITALY; MALE; MIDDLE AGED; ODDS RATIO; PRESCRIPTIONS, DRUG; PREVALENCE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SEX DISTRIBUTION;

EID: 22044439599     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-864124     Document Type: Article

References (17)

1. Barbui C, Campomori A, Mezzalira L et al. Psychotropic drug use in Italy 1984-1999: impact of regulatory changes. Int Clin Psychopharmacol 2001; 16: 227-233
2. Barbui C, Ciuna A, Nosé M et al. Off-label and non-classical prescriptions of antipsychotic agents in ordinary inpatient practice. Acta Psychiatr Scand 2004; 109: 275-278
3. Barbui C, Tansella M, Garattini S. Varying and "atypical" indications for atypical antipsychotics. Psychopharmacol 2003; 169: 205-206
4. Fleischhacker WW and the European Group for Research in Schizophrenia. Second-generation antipsychotics: discrepancies between licensed indications, evidence base and actual use. Psychopharmacol 2003; 169: 207-10
5. Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. Eur Psychiatry 2000; 15: 220-226
6. Geddes J, Freemantle N, Harrison P et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-1376
7. Hamann J, Ruppert A, Auby P et al. Antipsychotic prescribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. Int Clin Psychopharmacol 2003; 18: 237-242
8. Hermann RC, Yang D, Ettner SL, Marcus SC, Yoon C, Abrahm M. Prescriptions of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatr Serv 2002; 53: 425-430
9. Kapur S, Remington G. Atypical antipsychotics. Patients value the lower incidence of extrapyramidal side effects. BMJ 2000; 321: 1360-1361
10. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-1589
11. Percudani M, Barbui C. Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. J Clin Psychiatry 2003; 64: 1293-1299
12. Procyshyn RM, Thompson B. Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry 2004; 37: 12-7
13. Raschetti R, Spila-Alegiani S, Diana G et al. Antipsychotic drug prescription in general practice in Italy. Acta Psychiatr Scand 1993; 87: 317-321
14. Regione Lombardia. Regional Community Health Plan. 2002-2004 Accessed at www.sanita.regione.lombardia.it.
15. Rosenheck R, Perlick D, Bingham S et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 2003; 290: 2693-2702
16. Volavka J, Czobor P, Sheitman B et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159: 255-262
17. Weiss E, Hummer M, Koller D et al. Off-label use of antipsychotic drugs. J Clin Psychopharmacol 2000; 20: 695-698